SETD2 and cancer: MSIsensor scores in patients with SETD2 mutant cancer (0.12; 0.01–0.84) were significantly higher than the scores in patient with SETD2 nonmutant cancer (0.05, 0.00–0.31; P < 0.0001; Fig. 1f).